Skip Navigation

David A. Barbie, MD

Medical Oncology

Make an Appointment
Watch Video


  • Associate Director of the Robert and Renée Belfer Center for Applied Cancer Research
  • Physician
  • Associate Professor of Medicine, Harvard Medical School


Clinical Interests

  • KRAS targeted therapy
  • Lung cancer
  • Translational oncology

Diseases Treated

Contact Information

  • Appointments877-332-4294 (new)
    617-632-6190 (established)
  • Office Phone Number617-632-6049
  • Fax617-632-5786

Board Certification:

  • Internal Medicine, 2005
  • Medical Oncology, 2008


  • Dana-Farber/Partners CancerCare, Medical Oncology


  • Massachusetts General Hospital, Chief Resident in Internal Medicine
  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Recent Awards:

  • NIH R01 Award 2015
  • V Foundation Scholar Award 2012
  • ASCO Young Investigator Award 2009
  • NIH K08 Award 2010


Translational Oncology/KRAS Targeted Therapy

My interest as a medical oncologist and cancer biologist is to identify novel targets for cancer therapy. Specifically, I have focused on lung cancer clinically with a particular interest in targeting KRAS mutations, which have remained refractory to current therapies.

We previously found that TBK1, a kinase that is normally involved in immune cell signaling, prevents apoptosis in cancer cells driven by oncogenic KRAS. Others have found that inhibition of the NF-kB and STAT pathways, in which TBK1 is involved, also results in impaired tumor growth in KRAS-driven mouse lung cancer. Recently, we discovered that a kinase inhibitor, momelotinib, inhibits TBK1 and JAK signaling and has activity in mouse models of Kras-driven lung cancer. Based on these findings, we have opened a trial together with Gilead Sciences combining momelotinib with the MEK inhibitor trametinib in treatment refractory KRAS mutant lung cancer.

My overall goal is to continue this effort clinically and in the lab to refine combination therapy for KRAS-driven lung cancer and improve outcomes for this challenging disease.


Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions